{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2
  ],
  "modelUsed": "gemini-3-flash-preview",
  "metadata": {
    "studyName": "ARCHES: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety S",
    "titles": [
      {
        "id": "title_1",
        "text": "ARCHES: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)",
        "type": {
          "code": "Official Study Title",
          "codeSystem": "USDM",
          "decode": "Official Study Title"
        },
        "instanceType": "StudyTitle"
      },
      {
        "id": "title_2",
        "text": "ARCHES",
        "type": {
          "code": "Study Acronym",
          "codeSystem": "USDM",
          "decode": "Study Acronym"
        },
        "instanceType": "StudyTitle"
      }
    ],
    "identifiers": [
      {
        "id": "sid_1",
        "text": "9785-CL-0335",
        "scopeId": "org_1",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "SponsorProtocolNumber",
          "codeSystem": "USDM",
          "decode": "Sponsor Protocol Number"
        }
      },
      {
        "id": "sid_2",
        "text": "2015-003869-28",
        "scopeId": "org_eudract",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "EudraCT",
          "codeSystem": "USDM",
          "decode": "EudraCT Number"
        }
      },
      {
        "id": "sid_3",
        "text": "74563",
        "scopeId": "org_unknown",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "IND",
          "codeSystem": "USDM",
          "decode": "FDA IND Number"
        }
      }
    ],
    "organizations": [
      {
        "id": "org_1",
        "name": "Astellas Pharma Global Development, Inc (APGD)",
        "type": {
          "id": "41b4fe15-5132-4674-bd29-3046ec21c5d7",
          "code": "C54086",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Pharmaceutical Company",
          "instanceType": "Code"
        },
        "identifier": "Astellas Pharma Global Development, Inc (APGD)",
        "identifierScheme": "DUNS",
        "instanceType": "Organization"
      },
      {
        "id": "org_2",
        "name": "Medivation, a wholly owned subsidiary of Pfizer",
        "type": {
          "id": "ab184a8f-1af9-4b53-8082-9b346f3ded4e",
          "code": "C54086",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Pharmaceutical Company",
          "instanceType": "Code"
        },
        "identifier": "Medivation, a wholly owned subsidiary of Pfizer",
        "identifierScheme": "DUNS",
        "instanceType": "Organization"
      }
    ],
    "roles": [
      {
        "id": "role_1",
        "name": "Sponsor",
        "code": {
          "code": "Sponsor",
          "codeSystem": "USDM",
          "decode": "Sponsor"
        },
        "organizationIds": [
          "org_1"
        ],
        "instanceType": "StudyRole"
      },
      {
        "id": "role_2",
        "name": "Co-Sponsor",
        "code": {
          "code": "Co-Sponsor",
          "codeSystem": "USDM",
          "decode": "Co-Sponsor"
        },
        "organizationIds": [
          "org_2"
        ],
        "instanceType": "StudyRole"
      }
    ],
    "indications": [
      {
        "id": "ind_1",
        "name": "Metastatic Hormone Sensitive Prostate Cancer (mHSPC)",
        "isRareDisease": false,
        "instanceType": "Indication",
        "description": "Patients with metastatic hormone sensitive prostate cancer"
      }
    ],
    "studyPhase": {
      "code": "Phase3",
      "codeSystem": "USDM",
      "decode": "Phase3"
    },
    "studyType": "Interventional"
  },
  "rawResponse": {
    "titles": [
      {
        "id": "title_1",
        "text": "ARCHES: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)",
        "type": {
          "code": "OfficialStudyTitle",
          "codeSystem": "http://www.cdisc.org/USDM/titleType",
          "decode": "Official Study Title"
        },
        "instanceType": "StudyTitle"
      },
      {
        "id": "title_2",
        "text": "ARCHES",
        "type": {
          "code": "StudyAcronym",
          "codeSystem": "http://www.cdisc.org/USDM/titleType",
          "decode": "Study Acronym"
        },
        "instanceType": "StudyTitle"
      }
    ],
    "identifiers": [
      {
        "id": "sid_1",
        "text": "9785-CL-0335",
        "identifierType": "SponsorProtocolNumber",
        "issuingOrganization": "Astellas Pharma Global Development, Inc (APGD)",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_2",
        "text": "2015-003869-28",
        "identifierType": "EudraCT",
        "issuingOrganization": "EudraCT",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_3",
        "text": "74563",
        "identifierType": "IND",
        "issuingOrganization": "FDA",
        "instanceType": "StudyIdentifier"
      }
    ],
    "organizations": [
      {
        "id": "org_1",
        "name": "Astellas Pharma Global Development, Inc (APGD)",
        "type": {
          "code": "Sponsor",
          "codeSystem": "http://www.cdisc.org/USDM/organizationType",
          "decode": "Sponsor"
        },
        "role": "Sponsor",
        "instanceType": "Organization"
      },
      {
        "id": "org_2",
        "name": "Medivation, a wholly owned subsidiary of Pfizer",
        "type": {
          "code": "CoSponsor",
          "codeSystem": "http://www.cdisc.org/USDM/organizationType",
          "decode": "Co-Sponsor"
        },
        "role": "Co-Sponsor",
        "instanceType": "Organization"
      }
    ],
    "studyPhase": {
      "code": "Phase3",
      "codeSystem": "http://www.cdisc.org/USDM/studyPhase",
      "decode": "Phase 3"
    },
    "studyType": "Interventional",
    "indication": {
      "id": "ind_1",
      "name": "Metastatic Hormone Sensitive Prostate Cancer (mHSPC)",
      "description": "Patients with metastatic hormone sensitive prostate cancer",
      "instanceType": "Indication"
    }
  }
}